Welcome to our dedicated page for Bausch + Lomb Corporation news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb Corporation stock.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) is a global eye health company that regularly issues news on its business segments, financing activities, partnerships and product pipeline. As an ophthalmic goods manufacturer with operations in vision care, surgical products and ophthalmic pharmaceuticals, the company’s announcements cover a broad range of topics relevant to investors and those following the eye health sector.
News updates include financial results, such as quarterly revenue performance across the Vision Care, Surgical and Pharmaceuticals segments, as well as details on operating income, adjusted metrics and guidance ranges. The company also uses press releases to outline strategic plans and multi-year financial targets, describe its product pipeline in areas like dry eye, glaucoma, ocular surface pain and age-related macular degeneration, and highlight clinical-stage programs and anticipated launches across consumer, pharmaceutical, surgical and contact lens businesses.
Bausch + Lomb’s news flow also features information on capital structure and liquidity, including amendments to its credit agreement, new term loan tranches, revolving credit facilities and senior secured notes offerings, along with the intended use of proceeds for refinancing existing debt. Governance and leadership developments, such as board appointments, committee assignments and changes related to director nomination agreements, are disclosed through current reports and accompanying press releases.
In addition, the company issues news about partnerships and initiatives in eye health, including collaborations with organizations focused on glaucoma research and awareness, and sustainability programs like the ONE by ONE Recycling Program and the Every Contact Counts program. For readers tracking BLCO, this news page aggregates these updates so they can review company communications on financial performance, strategic direction, product development, governance and eye health initiatives in one place.
Bausch + Lomb (NYSE/TSX: BLCO) has launched ASANA™ gas permeable (GP) lenses in the United States, expanding its Specialty Vision Products portfolio. The comprehensive ASANA portfolio includes spherical, aspheric, toric, multifocal, reverse geometry and keratoconic lenses, designed to address complex vision challenges.
The ASANA lenses feature enhanced durability, maintaining shape throughout daily wear while resisting protein buildup. Eye care professionals receive support through consultant assistance for lens fittings, rapid manufacturing and shipping, and a 120-day EZ-Exchange™ Warranty Program with unlimited lens remakes. The lenses are custom-made exclusively with Boston® materials and are particularly beneficial for patients with high corneal astigmatism, severe refractive errors, keratoconus, and post-surgical vision correction needs.
Bausch + Lomb (NYSE/TSX: BLCO) announced changes to its Board of Directors following the termination of the Amended and Restated Director Appointment and Nomination Agreement with Carl C. Icahn and his affiliates. The agreement ended after the Icahn group's net long position in Bausch Health Companies Inc. fell below the required threshold.
As a result, Brett M. Icahn and Gary Hu have resigned from the Bausch + Lomb Board of Directors. Chairman and CEO Brent Saunders acknowledged their contributions over the past three years.
Bausch + Lomb (NYSE/TSX: BLCO), a global eye health company, has announced its participation in two upcoming investor conferences in September 2025. At the J.P. Morgan European Leveraged Finance Conference on September 3 in London, CFO Sam Eldessouky will conduct investor meetings.
Additionally, CEO Brent Saunders and CFO Sam Eldessouky will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 8 at 7:45 a.m. ET in New York. The Morgan Stanley presentation will be available via webcast on the company's Investor Relations website.
Bausch + Lomb (NYSE/TSX: BLCO) reported Q2 2025 financial results with total revenue of $1.278 billion, representing a 5% increase as reported and 3% growth on a constant currency basis compared to Q2 2024. The company posted a GAAP net loss of $62 million and Adjusted EBITDA of $191 million.
By segment, Vision Care revenue grew 8% to $753 million, Surgical increased 3% to $216 million, while Pharmaceuticals remained flat at $309 million. The company has raised its full-year 2025 guidance, now projecting revenue between $5.050B - $5.150B with 5-7% constant currency growth.
Notable achievements include reaching $1 billion in trailing 12-month revenue across the dry eye portfolio and resuming full production of enVista® platform IOLs following a market return.
Bausch + Lomb (NYSE/TSX: BLCO) has announced the publication of Phase 3 study results for its LUMIFY Preservative Free redness reliever eye drops in Ophthalmology and Therapy. The study, involving 380 participants, demonstrated that the preservative-free formulation is non-inferior to the original LUMIFY in reducing ocular redness.
The clinical trial showed the new formulation delivers results in one minute and lasts up to eight hours. The study met its primary objective, with participants receiving single drops four times daily for four weeks. Both formulations demonstrated comparable safety profiles and low incidence of side effects like rebound redness when used as directed.
Bausch + Lomb (NYSE/TSX: BLCO) has launched "Eyes Tell the Story: The Impact of Dry Eye," a campaign aimed at educating the public about dry eye through personal stories, imagery, and new survey data. The initiative builds upon their 2024 "Know Your Dry Eye" educational campaign.
The company's latest survey revealed significant findings: 78% of sufferers desire more resources and education on dry eye, 62% incorrectly assume dry eye resolves itself after treatment, and 40% waited six months or more before seeking medical help. The campaign features collaboration with photographer Kayte Demont, who captured portraits of dry eye sufferers including interior designer Alvin Wayne and lifestyle blogger Brianne Manz.
According to the company, approximately 150 million U.S. adults experience occasional or frequent dry eye symptoms, with 38 million living with chronic dry eye disease. The campaign emphasizes the importance of early intervention and highlights that relief options range from over-the-counter drops to prescription treatments.
Bausch + Lomb (NYSE/TSX: BLCO), a global eye health company, has scheduled two important investor events. The company will release its second-quarter 2025 financial results on Wednesday, July 30, 2025, at 8:00 a.m. ET, followed by a conference call and live webcast to discuss results and provide a business update.
Additionally, Bausch + Lomb will host an investor day on Thursday, November 13, 2025, where it plans to present a business update and showcase its innovative product pipeline. Further details about the investor day will be provided closer to the event date.
Bausch + Lomb (NYSE/TSX: BLCO) has successfully completed several significant financing transactions. The company closed an upsized offering of €675 million senior secured floating rate notes due 2031 and executed a partial credit agreement refinancing including a $2.325 billion term B loan facility and an $800 million revolving credit facility.
The notes will bear interest at three-month EURIBOR plus 3.875% per year with a 0% floor. The term B loans carry an interest rate of 4.25% for SOFR Loans and 3.25% for ABR Loans. The proceeds were used to refinance existing debt facilities and pay related expenses.